semaglutide belmont A phase 2b randomized clinical trial found that biweekly bofanglutide, a novel #GLP1 receptor agonist, produced meaningful reductions in HbA1c, weight, and cardiometabolic risk factors in patients with #Type2Diabetes. In some cases MedFIT (@getmedfit) · Belmont, NC

Microchim Acta 189:457

The institutions faculty members have received six Nobel Prizes and include 24 members of the National Academy of Sciences, 25 members of the National Academy of Medicine, and 13 Howard Hughes Medical Institute Investigators

They dont

Brand-name Ozempic has been covered under ODB for eligible patients with type 2 diabetes who meet specific Limited Use criteria

In humans, we have recently shown that the GLP-1 RA dulaglutide tends to reduce fluid intake and lowers 24-hour urinary output in healthy volunteers (24)

In fact several pharma companies already have small molecule GLP-1 agonists in their pipelines